Circle secured a $92.5M funding round that positions its cyclin D1 program ahead of the clinical lead. The funding is connected to preclinical combination data supporting prioritization of CID-165 over CID-078, with deeper breast cancer response goals driving the shift. The strategy highlights how investors are increasingly underwriting combination potential and not just single-agent biology, especially in oncology areas where response depth and durability determine competitive value. For other developers, the round is a reminder that mid-stage capital allocation is closely tied to evidence that can translate into clearer differentiation—particularly when multiple assets are in play and teams must choose which program to accelerate.